



Academic Personnel Short Profile / Short CV

| | |
|-----------------------------|---|
| Institution: | The Cyprus Institute of Neurology and Genetics (CING) |
| Surname: | Papasavva |
| Name: | Panayiota |
| Rank/Position: | Haematologist |
| Program of Study: | MSc in Molecular Medicine / MSc in Medical Genetics / MSc in Neuroscience / MSc in Biomedical Research / MSc in Biotechnology / PhD in Molecular Medicine / PhD in Medical Genetics / PhD in Neuroscience |
| Scientific Domain: * | Blood Disorders |

**Field of Specialization*

Academic qualifications / (list by highest qualification)

| Qualification | Year | Awarding Institution | Department | Thesis title |
|----------------------------------|------|--|------------|---|
| PhD | 2021 | CING | MGTD | Genome-editing-mediated lineage-specific knockdown of disease modifiers as therapy of β - haemoglobinopathies |
| MSc | 2017 | CING | MGTD | Characterisation of gene therapy vectors and primary human haematopoietic cell cultures |
| Medical specialty in Haematology | 2013 | Public health department, Attica domain, Greece | | |
| Medical Degree | 2000 | Medical School of National and Kapodistrian University of Athens, Greece | | |



| Qualification | Year | Awarding Institution | Department | Thesis title |
|---------------|------|----------------------|------------|--------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |



Employment history in Academic Institutions/Research Centers – List by the three (3) most recent

| Period of employment | | Employer | Location | Position |
|----------------------|------------|----------------------------------|------------------|--------------------------|
| From | To | | | |
| April 2023 | Present | CING | Nicosia, Cyprus | Haematologist |
| February 2022 | March 2023 | CING | Nicosia, Cyprus | Postdoctoral researcher |
| 2014 | 2016 | Ygia Polyclinic Private Hospital | Limassol, Cyprus | Consultant Haematologist |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

Key refereed journal papers, monographs, books, conference publications etc. List the five (5) more recent and other five (5) selected –(max total 10)

| Ref. No. | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
|----------|------|---|---|--|-----------------|-------|
| 1 | 2023 | High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis. | Nikoletta Papaioannou, Petros Patsali, Basma Naiisseh, Panayiota L Papasavva, Lola Koniali, Ryo Kurita, Yukio Nakamura, Soteroula Christou, Maria Sitarou, Claudio Mussolino, Toni Cathomen, Marina Kleanthous and Carsten Werner Lederer | Frontiers in Genome Editing 2023 Mar 8:5:1141618. doi: 10.3389/fgeed.2023.1141618. eCollection 2023. | 8:5:11 41618 | |

| Ref. No. | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
|----------|------|--|--|--|-----------|-------|
| 2 | 2022 | Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies. | Carsten W. Lederer, Lola Koniali, Tina Buerki-Thurnherr, Panayiota L. Papasavva, Stefania La Grutta, Amelia Licari, Frantisek Staud, Donato Bonifazi, and Marina Kleanthous. | Pharmaceutics 2022;14(4):793. https://doi.org/10.3390/pharmaceutics14040793 | 14(4):793 | 793 |
| 3 | 2022 | CRISPR Editing Enables Consequential Tag-Activated MicroRNA-Mediated Endogene Deactivation. | Panayiota L. Papasavva, Petros Patsali, Constantinos C. Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, Carsten W. Lederer | Int J Mol Sci. 2022, 23(3):1082. https://doi.org/10.3390/ijms23031082 | 23(3) | 1082 |
| 4 | 2021 | Distinct miRNA Signatures and Networks Discern Fetal from Adult Erythroid Differentiation and Primary from Immortalized Erythroid Cells. | Panayiota L. Papasavva, Nikoletta Y. Papaioannou, Petros Patsali, Ryo Kurita, Yukio Nakamura, Maria Sitarou, Soteroulla Christou, Marina Kleanthous, and Carsten W. Lederer. | Int. J. Mol. Sci. 2021, 22(7):3626 https://doi.org/10.3390/ijms22073626 | 22(7) | 3626 |
| 5 | 2020 | Relative and absolute quantification of aberrant and normal splice variants in HBBIVSI- 110(G>A) β -thalassemia. | Petros Patsali, Panayiota Papasavva, Soteroulla Christou, Maria Sitarou, Michael N. Antoniou, Carsten W. Lederer *, Marina Kleanthous | Int. J. Mol. Sci. 2020, 21(18), 6671; doi: 10.3390/ijms21186671 | 21(18) | 6671 |

| Ref. No. | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
|----------|------|---|--|---|-------------------------|---------------|
| 6 | 2019 | Correction of IVS I-110(G>A) beta-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells. | Petros Patsali, Giandomenico Turchiano, Panayiota Papasavva, Marianna Romito, Constantinos C. Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I. Cornu, Michael N. Antoniou, Carsten W. Lederer, Toni Cathomen, Marina Kleanthous | Haematologica 2019 April. doi:10.3324/haematol.2018.215178 (2019) | 2019 Nov;10 4(11) | e497- e501 |
| 7 | 2019 | Rare opportunities: CRISPR/Cas9-based therapy development for rare genetic diseases | Papasavva P, Kleanthous M, Lederer CW | Mol. Diagnosis Ther. 23, 201–222 (2019); https://doi.org/10.1007/s40291-019-00392-3 | 23 | 201– 222 |
| 8 | 2018 | Short-hairpin RNA against aberrant HBBIVS1-110(G>A) mRNA restores β -globin levels in a novel cell model and acts as mono- and combination therapy for β -thalassemia in primary hematopoietic stem cells | Patsali P, Papasavva P, Stephanou C, Christou S, Sitarou M, Antoniou M, Lederer CW, Kleanthous M. | Haematologica 2018 Apr 26. doi: 10.3324/haematol.2018.189357. PMID: 29700171 | 103(9) | e419- e423 |
| 9 | 2017 | Rapid and sensitive assessment of globin chains for gene and cell therapy of haemoglobinopathies | Loucari CC, Patsali P, van Dijk TB, Stephanou C, Papasavva P, Zanti M, Kurita R, Nakamura Y, Christou S, Sitarou M, | Hum Gene Ther Methods 2018 Jan 12. doi: 10.1089/hgtb.2017.190 | 29(1) | 60-74 |



| Ref. No. | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
|----------|------|---|---|--|------|---------|
| | | | Philipsen S, Lederer CW, Kleanthous M. | | | |
| 10 | 2017 | Suitability of Small Diagnostic Peripheral-blood Samples for Cell-therapy Studies | Stephanou C, Papasavva P, Zachariou M, Patsali P, Epitropou M, Ladas P, Al-Abdulla R, Christou S, Antoniou MN, Lederer CW, Kleanthous | M. Cytotherapy 2017 Feb;19(2):311-326. doi: 10.1016/j.jcyt.2016.11.007. PMID: 28088294 | 9(2) | 311-326 |

Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10)

| Ref. No. | Date | Topic | International / Local | Location* | Role in Exhibition |
|----------|------|-------|-----------------------|-----------|--------------------|
| 1 | | | | | |
| 2 | | | | | |
| 3 | | | | | |
| 4 | | | | | |
| 5 | | | | | |
| 6 | | | | | |
| 7 | | | | | |
| 8 | | | | | |
| 9 | | | | | |
| 10 | | | | | |

*Specify venue, geographic location etc



**Research Projects. List the five (5) more recent and other five (5) selected
(max total 10)**

| Ref. No. | Date | Title | Funded by | Project Role* |
|----------|----------------------------|--|--|----------------------|
| 1 | 01/04/2022 – 31/03/2023 | Preclinical validation of HBBIVSI-110(G>A) - specific gene editing as advanced therapy for thalassemia | RESTART 2016- 2020 Programme for Research, Technological Development and Innovation RESEARCH AND INNOVATION FOUNDATION | Researcher |
| 2 | 2019-2022 | βTHAL-GT4U_Personalized Gene Therapy for β-thalassaemia_EXCELLENCE/1216/0092 | Funded by RIF - Excellence Hubs | Research team member |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Project Role: i.e. Scientific/Project Coordinator, Research Team Member, Researcher, Assistant Researcher, other

**Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees.
 List the five (5) more recent (Optional Entry)**

| Ref. No. | Period | Organization | Title of Position or Service | Key Activities |
|----------|--------|--------------|------------------------------|----------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |

**Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected.
 (max total 10) (Optional Entry)**

| Ref. No. | Date | Title | Awarded by: |
|----------|------------|---|--|
| 1 | Nov 2021 | Best Poster Award, 1st Prize. Panayiota L. Papisavva, Petros Patsali, Constantinos C. Loucari, Lola Koniali, Nikoletta Y. Papaioannou, Basma Naissheh, Marina Kleanthous, and Carsten W. Lederer, Exploring miRNAs as tools for therapy: Tag-activated microRNA- mediated endogene deactivation (TAMED), 9th IMBMC congress, Nov 18th to 20th, 2021, Nicosia, Cyprus. Poster. | 9th IMBMC congress |
| 2 | 17/11/2018 | 3rd Prize for Best Poster. Papisavva P, Patsali P, Loucari C, Obaid M, Stais E, Lederer CW, Kleanthous M. 17/11/2018 CRISPR/Cas9-based disruption of beta-thalassemia disease modifiers. 6th International Multithematic Bio-Medical Congress, Nicosia, Cyprus. Poster | 6th International Multithematic Bio-Medical Congress |



| Ref. No. | Date | Title | Awarded by: |
|----------|--------------------------------|---|---|
| 3 | 2016–2017 and 2017– 2018 | Highest ranking student award for the academic years 2016–2017 and 2017–2018, CING, Cyprus. Best Poster Award, 1st Prize. Panayiota L. Papasavva, Petros Patsali, Constantinos C. Loucari, Lola Koniali, Nikoletta Y. Papaioannou, Basma Naissheh, Marina Kleanthous, and Carsten W. Lederer, Exploring miRNAs as tools for therapy: Tag-activated microRNA- mediated endogene deactivation (TAMED), 9th IMBMC congress, Nov 18th to 20th, 2021, Nicosia, Cyprus. Poster. | CING, Cyprus. |
| 4 | 2000 | Award of excellence , 2000, Medical School of National and Kapodistrian University of Athens, Greece. | Medical School of National and Kapodistrian University of Athens, Greece. |
| 5 | | | |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | | | |



**Other Achievements. List the five (5) more recent and other five (5) selected.
(max total 10) (Optional Entry)**

| Ref. No. | Date | Title | Key Activities: |
|----------|------|-------|-----------------|
| 1 | | | |
| 2 | | | |
| 3 | | | |
| 4 | | | |
| 5 | | | |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | | | |